EUCTR2021-005057-87-FR进行中（未招募）1 期
A placebo-controlled, proof-of-concept study to evaluate the safety and efficacy of Lanifibranor alone and in combination with the sodium-glucose transport protein 2 (SGLT2) inhibitor EmpaGliflozin in patiEnts with Non-alcoholic steatohepatitis (NASH) and type 2 Diabetes mellitus (T2DM) - LEGEND
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 63
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •For an eligible patient, all inclusion criteria must be answered yes” at Screening and re-confirmed at Baseline (i.e., before randomization). Laboratory tests taken during the screening period will be used to determine eligibility. If information cannot be confirmed in the medical record, responses will be obtained in a patient interview:
- •1.Able to understand the nature of the study, willing and able to comply with the study procedures and restrictions, and willing to provide informed consent obtained before any study-related activities
- •2.The patient is willing to continue on the study in case of moving or relocating to a different region/city where there would be no active study site
- •3.Able to communicate meaningfully with the Investigator and legally competent to provide written informed consent
- •4.Male or female, aged = 18 years at the time of signing informed consent
- •5.Diagnosis of NASH
- •a.based on a historical (within 12 months prior to Screening) liver biopsy with a non-alcoholic fatty liver disease activity score (NAS) = 4 with a score of one or more in each sub-component (steatosis, hepatocyte ballooning, lobular inflammation) and no documented cirrhosis in the last 12 months prior to Screening OR
- •b.high-risk NASH defined as cT1 > 875 ms assessed by LiverMultiScan® at Screening
- •6.HbA1c at screening = 7.0 and = 10.0%, on diet alone, or on metformin (= 1,000 mg/day), and/or dipeptidyl peptidase 4 inhibitor (DPP-IVi) therapy. Doses have to be stable for 3 months prior to informed consent. These medicines will be continued at stable doses during the entire study.
- •7.Negative pregnancy test at Screening for females of childbearing potential or at least two-year post-menopausal. Women of childbearing potential (i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile) have to use a highly effective method of contraception throughout the study and for one month after treatment discontinuation. Highly effective contraceptive methods are defined as follows: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner (provided he is her sole sexual partner and he has received medical assessment of the surgical success), and true sexual abstinence (when this is in line with the preferred and usual lifestyle of the patient) whereas periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 63
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 16
排除标准
- •Liver-related:
- •1.Documented causes of chronic liver disease other than NASH
- •2.Histologically documented liver cirrhosis (fibrosis stage F4); or diagnosis of cirrhosis at Screening
- •3.History or current diagnosis of hepatocellular carcinoma (HCC)
- •4.History of or planned liver transplant
- •5.Documented history of human immunodeficiency virus (HIV) infection
- •6.ALT or AST > 5 × upper limit of normal (ULN) at Screening
- •7.Abnormal liver function as defined by central laboratory evaluation of any of the following:
- •a.Albumin < lower limit of normal range (LLN)
- •b.International normalized ratio (INR) = 1.3 (unless patient is on anticoagulants)
- •c.Total bilirubin level = 1.3 mg/dL (22.2 µmol/L)
- •8.Hemoglobin < 110 g/L (11 g/dL) for females and < 120 g/L (12 g/dL) for males
- •9.White blood cell count (WBC) < LLN
- •10.Platelet count < 150,000/µL
- •11.Alkaline phosphatase (ALP) > 2 × ULN
- •12.Patient currently receiving any approved treatment for NASH or obesity
- •13.Current or recent history (< 5 years) of significant alcohol consumption. No binge drinking during the last year.
- •14.Administration of drugs known to produce hepatic steatosis in the 6 months prior to Screening
- •Diabetes related:
- •15.Diabetes mellitus other than type 2
- •16.Diabetic ketoacidosis at Screening
- •17.Current treatment with GLP-1RA, insulin or sulfonylurea or treatment within the last 3 months prior to Screening
- •18.Patients on pioglitazone in the last 12 months prior to Screening
- •19.Patients on any of the following medications unless the patient has been on stable doses of such agents for the past 3 months before Screening: metformin, DPP-IVi, thiazide or furosemide diuretics, beta-blockers, or other chronic medications with known adverse effects on glucose tolerance levels. Patients taking systemic glucocorticoids will be excluded.
- •Obesity related:
- •20.BM) > 45 kg/m2 at Screening
- •21.Weight change > 5% in the 3 months prior to Screening
- •22.Introduction of an anti-obesity drug or restrictive bariatric surgery in the past 12 months prior to Screening or planned bariatric surgery through Week 24
- •23.Participation in an organized weight loss program in the past 6 months prior to Screening or planned participation through Week 24
- •Cardiovascular related:
- •24.History of (within 3 months prior to Screening) or current unstable cardiac dysrhythmias
- •25.NT-proBNP > 900 pg/mL
- •26.Unstable heart failure
- •27.Any other clinically significant cardiovascular event requiring hospitalization within 6 months before Screening
- •28.Uncontrolled hypertension at Screening (systolic blood pressure [SBP] > 160 mmHg and/or diastolic blood pressure [DBP] > 100 mmHg
- •29.Stroke or transient ischemic attack within 6 months prior to Screening
- •General safety:
- •30.Significant systemic or major illnesses other than liver disease that would preclude treatment with lanifibranor and/or empagliflozin
- •31.Any condition which might jeopardize a patient’s safety or compliance with the protocol, or warrants exclusion from the study
- •32.Cancer: Presence or history of malignancy within 5 years prior to Screening and/or active neoplasm at Screening.
- •33.History of bladder disease and/or persistent hematuria within 6 months prior to Screening or current hematuria unless due to a urinary tract infection
- •34.Renal impairment measured as eGFR < 60 mL/min as determined by MDRD
- •35.Total creatine kinase > 1.5 x ULN
研究者
相似试验
招募中
2 期
A placebo-controlled, proof-of-concept study to evaluate the safety and efficacy of Lanifibranor alone and in combination with the sodium-glucose transport protein 2 (SGLT2) inhibitor EmpaGliflozin in patiEnts with Nonalcoholic steatohepatitis (NASH) and type 2 Diabetes mellitus (T2DM)Diabetes type 2Non-alcoholic Steatohepatitisliver inflammation1001965410018424diabetesNL-OMON53417Inventiva S.A.5
进行中（未招募）
1 期
A clinical study to find out how safe and effective Lanifibranor is in patientswith Non-alcoholic steatohepatitis (NASH) and type 2 Diabetes.Lanifibranor will be studied when taken alone or in combination withEmpagliflozin.EUCTR2021-005057-87-NLInventiva S.A.63
已完成
2 期
Omega-3 supplements for improving peripheral nerve health in type-1 diabetesACTRN12618000705280The University of Melbourne43
进行中（未招募）
不适用
A Randomized, placebo controlled study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva®), onprogression-free survival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapy.EUCTR2008-001736-12-BEF. Hoffmann-La Roche Ltd150
进行中（未招募）
不适用
A Randomized, placebo controlled study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva®), onprogression-free survival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapy.To investigate in a randomized fashion if the addition of targeted IGF-1R blockade with R1507 has additional clinical benefit when combined with erlotinib in patients with advanced NSCLC who have failed at least one, but no more than two standard chemotherapy regimens. The study will also investigate 2 doses and schedules of R1507 combined with erlotinib compared with erlotinib and placebo, and assess the safety and tolerability of the combination in this patient population.MedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBMedDRA version: 9.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2008-001736-12-DEF. Hoffmann-La Roche Ltd150